There is an ever-growing demand for vaccines and therapeutics that can effectively prevent or treat a wide range of infectious diseases. Preclinical efficacy testing determines the efficacy of vaccine and therapeutic candidates and provides insights into dose and dose scheduling.

TICRO scientists have established expertise with in vivo infectious disease models. We offer a broad spectrum of established infection models to assess preclinical efficacy of vaccine candidates in challenge studies and anti-infective agents. We offer murine models of infection using a broad range of pathogens, with a focus on respiratory infections, including: Influenza A and B viruses, Mycobacterium tuberculosis, Pseudomonas aeruginosa, Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae, Yersinia enterocolitica, Yersinia pestis, Listeria monocytogenes, Campylobacter jejunii, and Francisella tularensis (strain LVS). We have the scientific expertise to tailor these models to client specifications and develop new infectious disease models to meet the needs of clients.

For more information, please contact:

William Reiley, Ph.D.
Senior CRO Program Manager
(518) 891-3080, ext. 315
TICRO@trudeauinstitute.org